Endocrine Abstracts (2009) 20 P414

Thyroid dysfunctions and serum creatine kinase levels in statins-using patients with hyperlipidemia

Taner Bayraktaroglu1,4, Mesut Ozkaya2, Faruk Kutluturk3,4, Adil Dogan Azezli4 & Yusuf Orhan4


1Endocrinology and Metabolism, Faculty of Medicine, Zonguldak Karaelmas University, Zonguldak, Turkey; 2Endocrinology and Metabolism, Faculty of Medicine, Sutcuimam University, Kahramanmaras, Turkey; 3Endocrinology and Metabolism, Faculty of Medicine, Gaziosmanpasa University, Tokat, Turkey; 4Endocrinology and Metabolism, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.


Introduction: Hypothyroidism is a well-known cause of secondary dyslipidemia, and its link to atherosclerosis has been known for long time. The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) offer important benefits for the large population of individuals at high risk for coronary heart disease. It was aimed to invastigation the relations of the secondary hyperlipidemia included overt and subclinical hypothyroidism and increased serum creatine kinase (CK) levels in patients who were taken statins to treatment for hyperlipidemia, retrospectively.

Materials and method: There were 1765 patients who were taken statins for hyperlipidemia in last 5 years. The rates of hypothyroidism and subclinical hypothyroidism were determined, then increased serum CK levels as a statin induced myopathy were analysed.

Results: There were 51 (2.9%) patients with subclinical hypothyroidism and 26 (1.5%) hypothyroidism in study population. However, increased CK levels were not determined in subjects with thyroid dysfunctions.

Conclusion: The rate of hypothyroid-induced myopathy is unknown. Patients’ thyroid status should always be considered before initiating lipid-lowering medications. Statins offer important benefits with decreased statin induced myopathy for the large population of individuals at high risk for coronary heart disease.

Article tools

My recent searches

No recent searches.